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Purpose: To develop a nomogram using transrectal ultrasound (TRUS)-derived information for predicting high grade (HG) prostate 
cancer (PCa) on initial biopsy.
Methods: Data were collected on 1,048 men with serum prostate-specific antigen (PSA) levels 4.0 to 9.9 ng/mL who underwent an 
initial prostate biopsy. Two logistic regression-based nomograms were constructed to predict the detection of PCa. Nomogram-1 
incorporated age, digital rectal examination, PSA and percent free PSA data, whereas nomogram-2 incorporated those factors plus 
TRUS-derived information (i.e., prostate volume and the presence of hypoechoic lesions). The prediction of any PCa and HGPCa (Gleason 
score≥7) were determined. Twenty percent of the data were randomly reserved for study validation, and the predictive accuracies of 
the two nomograms were directly compared.
Results: Of the 1,048 men who underwent biopsy, 216 (20.6%) were found to have any PCa, and 97 (9.3%) were found to have HGPCa. 
All six risk factors were found to be independent predictors for both any PCa and HGPCa. The area under curve (AUC) for nomogram-2 
was 0.76 (95% confidence interval [CI], 0.72 to 0.81) for predicting any PCa, and 0.83 (95% CI, 0.79 to 0.88) for predicting HGPCa. These 
AUCs were greater than those for nomogram-1 (0.72 [95% CI, 0.68 to 0.76 for any PCa; P<0.001], 0.78 [95% CI, 0.72 to 0.83 for HGPCa; 
P<0.001]). Removing the TRUS-derived information from nomogram-2 resulted in an incremental AUC decrease of 0.052 for any PCa 
and 0.063 for HGPCa.
Conclusions: The nomogram using TRUS-derived information had a high predictive accuracy for HGPCa on initial prostate biopsy.
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INTRODUCTION
Prostate cancer (PCa) is the most common nonskin cancer in 
men in the United States (US), with an estimated 186,320 new 
cases in 2008 [1]. The serum prostate-specific antigen (PSA) 
test is commonly used as a diagnostic screening tool for de-
tecting PCa. A recent randomized European trial showed that 
while PCa screening decreased PCa mortality by 20%, it was 
associated with a high risk of overdiagnosis [2]. Approximate-
ly 1.5 million US men aged 40 to 69 years have a PSA level 
greater than 4.0 ng/mL, a value widely accepted as a positive 
test result [3].
 In men with intermediate PSA range (4 to 10 ng/mL), the 
detection rate of prostate biopsy is approximately 25%. In this 
range, PSA alone does not differentiate men with the benign 
prostatic disease from those with PCa due to its lack of speci-
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2. Baseline data information and primary end point
Demographic and laboratory data regarding age, serum total 
PSA level, percent free PSA, DRE findings and TRUS-derived 
information (prostate volume and presence of hypoechoic 
lesions) were obtained by reviewing medical records. The 
serum total and free PSA values were measured using a PSA-
RIACT assay system (CIS Bio International, Gif-Sur-Yvette, 
France). All patients underwent TRUS-guided laterally direct-
ed sextant or systematic 10–12 core biopsies of the prostate. 
A C9-5ec probe was used with an IU-22 ultrasonography unit 
(Philips Medical Systems, Bothell, WA, USA). Prostate volume 
was calculated by TRUS using the following ellipsoid formula: 
volume=(π/6)×length×width×height. Six to 12 (median, 
10) ultrasound-guided needle core biopsies were performed 
using an 18-gauge spring-loaded biopsy device. The primary 
end point was the histologic presence of adenocarcinoma 
of the prostate in the biopsy specimen. All grading was per-
formed by genitourinary pathology specialists at our institute, 
and was based on the Gleason scoring system.
3. Statistical analysis
The primary endpoint was detection of any PCa or HGPCa 
(Gleason score>7) in the biopsy material. Of 1,048 patients, 
838 (80%) were randomly selected for model building, while 
the remaining 20% (n=210) were reserved for model vali-
dation. Factors considered potentially associated with an 
increased risk of a positive biopsy result were compared be-
tween any cancer/HGPCa and controls, including age, total 
PSA level, percent free PSA, DRE findings and TRUS-derived 
information (prostate volume and TRUS findings). Age, total 
PSA, percent free PSA and prostate volume were analyzed 
as continuous variables, and DRE and TRUS findings were 
analyzed as categorical variables. Univariate and multivari-
ate logistic regression analysis was used to examine whether 
factors alone or in combination affected the prediction of the 
presence of any or HGPCa. Ordinal logistic regression was 
used to model the probability of having any or HGPCa. The lo-
gistic regression model was the basis for constructing a nomo-
gram. To construct nomograms predicting any or HGPCa, two 
outcome levels were defined: no cancer/any cancer; and no 
cancer + low grade cancer (Gleason score<6)/HGPCa (Glea-
son score>7). The predictive accuracy of a nomogram not 
using TRUS-derived information (nomogram-1) was directly 
compared to that of a nomogram using TRUS-derived infor-
mation (nomogram-2). Nomogram validation comprised two 
activities. First, using the validation data set, discrimination 
was quantified using the area under the receiver operating 
characteristic curve (AUC). Second, calibration accuracy was 
ficity [4]. Therefore, several clinical and laboratory variables 
have been proposed in an attempt to improve the sensitiv-
ity and specificity of detecting PCa in men with intermedi-
ate PSA levels [5]. Models such as nomograms and artificial 
neural networks have been developed to integrate multiple 
prebiopsy risk factors, to predict initial biopsy outcomes on 
an individual basis [6-8]. Successful modeling will reduce 
the number of unnecessary prostate biopsies and assist in 
optimal disease management, and thus will have significant 
benefits in terms of costs and patient satisfaction. 
 Patients with high grade PCa (HGPCa) have a significantly 
worse prognosis compared with those with low grade PCa. 
Therefore, predicting the presence of HGPCa is important to 
treat these patients aggressively [9]. Transrectal ultrasound 
(TRUS) data (i.e., prostate volume and the presence of hy-
poechoic lesions) have been incorporated into conventional 
nomograms using serum PSA and digital rectal examination 
(DRE) to increase the predictive accuracy [10]. However, it 
remains unclear whether the inclusion of such TRUS-derived 
information improves the accuracy of HGPCa prediction in 
men with intermediate PSA levels. 
 In the present study, we developed a nomogram that in-
corporated TRUS-derived information for predicting HGPCa 
on initial biopsy in men with serum PSA levels of 4.0–9.9 ng/
mL and tested whether the addition of TRUS-derived infor-
mation would enhance nomogram accuracy for predicting 
HGPCa.
MATERIALS AND METHODS
1. Study subjects
The study included a total of 1,048 eligible men who visited 
the Asan Medical Center (Seoul, Korea) between December 
1997 and March 2008 for prostatic evaluation due to abnor-
mal DRE and/or PSA results. Eligible patients were unselect-
ed and were accrued consecutively. All subjects had PSA lev-
els ranging from 4.0 to 9.9 ng/mL. The enrolled subjects had 
visited hospitals for various reasons including PCa screening 
and voiding symptoms, and were included in the study re-
gardless of whether those visits were primary or referred. Pa-
tients who had active acute prostatitis, were in active urinary 
retention, had recently undergone prostatic manipulation 
or were on medications that may affect total PSA levels were 
excluded. The Institutional Review Board of the Asan Medical 
Center approved all sampling and data collection procedures, 
and written, informed consent was obtained from all partici-
pants.
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and for predicting HGPCa was 0.78 (95% CI, 0.72 to 0.83). For 
nomogram-2, the total AUC for predicting any PCa was 0.76 
(95% CI, 0.72 to 0.81), and for predicting HGPCa was 0.83 (95% 
CI, 0.79 to 0.88). Statistical analysis showed that nomogram-2 
was better than nomogram-1 at predicting the presence of 
both any PCa (P=0.001) and HGPCa (P<0.001). The calibra-
tion of nomogram-2 using the validation data set is shown in 
Fig. 2.
 We investigated which nomogram-2 risk factors were im-
portant for predicting PCa by removing one factor at a time 
and observing the effect on the AUC. We found that age was 
the most important predictor, with its removal resulting in an 
incremental decrease of 0.077 for any and 0.067 for HGPCa. 
The removal of percent free PSA resulted in an incremental 
AUC decrease of 0.003 and 0.025 for any and HGPCa, respec-
tively. The removal of all TRUS-derived information (prostate 
volume and presence of hypoechoic lesions) resulted in in-
cremental AUC decreases of 0.052 for predicting any PCa and 
0.063 for predicting HGPCa (Table 3). 
determined. All statistical analyses were performed using 
STATA ver. 10.1 (StataCorp LP., College Station, TX, USA).
RESULTS
Of the 1,048 men, 216 (20.6%) were found to have adenocar-
cinoma of the prostate at biopsy, while the remaining 832 
patients (79.4%) showed no evidence of cancer. Of the 216 
patients with cancer, 97 (44.9%) had a Gleason score >7 (HG-
PCa). Table 1 shows the comparison of factors associated with 
PCa between any cancer/HGPCa and controls. Multivariate 
analysis showed that all risk factors examined were indepen-
dently associated with PCa (Table 2).
 We constructed two nomograms to predict the presence of 
both any PCa and HGPCa according to biopsy results. Nomo-
gram-1 incorporated age, total PSA, percent free PSA and DRE 
findings, while nomogram-2 incorporated the same factors 
plus TRUS-derived information (prostate volume and pres-
ence of hypoechoic lesions) (Fig. 1). For nomogram-1, the to-
tal AUC for predicting any PCa was 0.72 (95% CI, 0.68 to 0.76), 
Table 1. Comparison of factors associated with any and high grade prostate cancer
Factor
Any cancer  
(n=216)
Control  
(n=832)
P-value High grade  
cancer (n=97)
Control  
(n=951)
P-value
Median age (yr) 67 62 <0.001a) 69 63 <0.001a)
      Mean (range) 66.8 (41–88) 61 (25–87) 67.6 (45–88) 61.7 (25–87)
Median PSA (ng/mL)   6.9   6.2 <0.001a)   7.6   6.2 <0.001a)
      Mean (range) 7.0 (4.0–9.9) 6.5 (4.0–9.9) 7.3 (4.0–9.0) 6.5 (4.0–9.9)
Median percent free PSA 15.4 17.4 0.03a) 13.9 18.1 <0.001a)
      Mean (range) 16.9 (4.6–43.2) 18.2 (1.2–51.1) <0.001b) 15.5 (6.0–43.2) 18.1 (1.2–21.1) <0.001b)
Digital rectal examination, n (%)
      No nodule 154 (71.3) 793 (88.1) 64 (66.0) 823 (86.5)
      Nodule   62 (28.7)   99 (11.9) 33 (34.0) 128 (13.5)
Median prostate volume 28.0 35.0 <0.001a) 26.6 34.2 <0.001a)
      Mean (range) 31.6 (11.0–92.0) 39.1 (10.0–169.3) 29.7 (13.0–78.3) 38.4 (11.0–169.9)
TRUS findings, n (%) <0.001b) <0.001b)
      Hypoechoic lesion (-) 155 (71.8) 687 (82.6) 54 (55.7) 788 (82.9)
      Hypoechoic lesion (+) 61 (28.2) 145 (17.4) 43 (44.3) 163 (17.1)
PSA, prostate-specific antigen; TRUS, transrectal ultrasound.
a)Wilcoxon rank-sum test. b)Fisher’s exact test.
Table 2. Multivariate analysis of factors associated with any and high grade prostate cancer
Factor
Any cancer High grade cancer
RR 95% CI P-value RR 95% CI P-value
Age 1.09 1.07–1.12 <0.001 1.10 1.07–1.13 <0.001
PSA 1.15 1.06–1.25 0.001 1.22 1.09–1.36 0.001
Percent free PSA 0.97 0.95–0.99 0.028 0.94 0.90–0.97 0.001
Abnormal DRE findings 2.00 1.31–3.05 0.001 1.89 1.09–3.30 0.024
Prostate volume 0.95 0.94–0.97 <0.001 0.95 0.93–0.97 <0.001
Abnormal TRUS findings 1.51 1.01–2.24 0.043 3.45 2.09–5.71 <0.001
RR, relative risk; CI, confidence interval; PSA, prostate-specific antigen; DRE, digital rectal examination; TRUS, transrectal ultrasound.
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DISCUSSION
The present report describes a nomogram for predicting HG-
PCa using TRUS-derived information in men with intermedi-
ate PSA levels. This is the first such nomogram reported to 
our knowledge. This nomogram incorporating TRUS-derived 
information outperformed a model not incorporating TRUS-
derived information in predicting any PCa as well as HGPCa. 
 In the present nomogram, although TRUS-derived infor-
mation was found to be a strong factor in predicting any PCa, 
it was particularly influential for predicting HGPCa. The in-
cremental drop in AUC when TRUS-derived information was 
removed from the model was 0.052 for any cancer and 0.063 
Table 3. Incremental drops in the AUC for each predictor vari-
ables when removed from the nomogram-2
Variable
Incremental drop in AUC
Any  
cancer
High grade  
cancer
AUC for nomogram-2 (95% CI) 0.76 (0.72–0.81) 0.83 (0.79–0.88)
Age 0.077 0.067
PSA 0.003 0.003
Digital Rectal Examination 0.004              0
Percent free PSA 0.003 0.025
Prostate volume 0.049 0.038
Abnormal TRUS findings 0.003 0.025
AUC, area under the receiver operating characteristic curve; CI, confidence 
interval; PSA, prostate-specific antigen; TRUS: transrectal ultrasound.
A B
Fig. 1. Logistic-based nomogram-2 prediction model for predicting (A) any and (B) high grade prostate cancer on initial biopsy. To 
obtain the predicted probability of cancer, locate the patient position for each variable on the horizontal axis and determine the as-
signed point value. The probability value for having cancer corresponds to the summed all points scale for all variables. PSA, prostate-
specific antigen; DRE, digital rectal examination; TRUS, transrectal ultrasound.
Fig. 2. Calibration of the nomogram-2 prediction model when predicting (A) any and (B) high grade cancer. Perfect predictions cor-
respond to the line with a slope of 1 (if the predictive model were perfect, triangles would lie on the 45° dotted line). 
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for HGPCa. Conversely, when TRUS data was incorporated 
into the nomogram, the increase in accuracy of predicting 
HGPCa was greater than the increase for predicting any PCa. 
In addition, the AUC was very high (0.83), even though uri-
nary voiding symptoms score and family history were not 
considered.
 The present nomogram developed in an Asian population 
is important given that the epidemiology and biology of PCa 
may differ between Western and Asian men. Therefore, it may 
be incorrect to directly apply nomograms developed in West-
ern countries to Asian populations. For example, although 
percent free PSA is the most important prebiopsy factor in im-
proving the specificity of PSA testing in men with intermediate 
PSA ranges in Western countries, it is not the most important 
factor in Korean men [4,11].
 Although several studies have described nomograms that 
included prostate volume as a predictive variable, to our 
knowledge only two studies have also included hypoechoic 
lesion data [7,12]. Garzotto et al. [7] incorporated TRUS data 
(presence of hypoechoic lesions and PSA density) into a no-
mogram predicting PCa in men with PSA levels of <10 ng/mL. 
The AUC for that model was 0.73, in contrast to 0.62 for the pre-
diction based on PSA alone. Kawakami et al. [12] also reported 
that predictive accuracy for detection of PCa was improved 
when TRUS-derived information was incorporated into a 
conventional nomogram using age, PSA and DRE (AUC=0.79 
ver. 0.73, P<0.05). In our study, the AUC was 0.76 when us-
ing a nomogram incorporating all factors, including TRUS-
derived information, indicating a similar predictive power 
for any prostate cancer as that of the nomogram reported by 
Kawakami et al. [12]. However, they did not examine HGPCa 
prediction, which most urologists are desirable to detect.
 Needle biopsy Gleason grade is routinely used to plan PCa 
patient counseling and management [13]. Many studies reveal 
an association between an increased biopsy Gleason score 
and decreased disease-free survival after radical prostatec-
tomy or radiation therapy [14-17]. In this context, predicting 
HGPCa is very important on initial biopsy in men with in-
creased serum PSA levels to help identify patients at high risk 
for aggressive PCa.
 Few studies have directly investigated predicting HGPCa in 
men undergoing prostate biopsy for elevated PSA. Thompson 
et al. [18] developed a predictive model of PCa from the place-
bo group of the Prostate Cancer Prevention Trial who under-
went prostate biopsies to assess HGPCa risk. They found that 
higher serum PSA levels, abnormal DRE results, advanced 
age at biopsy and African American race were predictive of 
high grade disease (Gleason score>7). Nam et al. [19] also 
constructed a nomogram to predict both the probability of 
any PCa as well as the probability of high grade cancer using 
age, ethnicity, family history, urinary voiding symptom score, 
percent free PSA and DRE findings. However, neither of these 
two studies incorporated TRUS-derived information into the 
nomogram for predicting the HGPCa.
 The association between TRUS-derived information and 
PCa aggressiveness remains unclear. Because small prostate 
volume has been reported to be associated with HGPCa after 
radical prostatectomy for PCa, we hypothesized that incorpo-
ration of prostate volume into the nomogram would increase 
the accuracy of the nomogram predicting HGPCa on initial 
prostate biopsy [20,21]. In addition, because we found that 
men with HGPCa were found to have more hypoechoic le-
sions compared with those with any PCa (44.3% ver. 28.2%), 
we also tested whether incorporating data regarding the pres-
ence of hypoechoic lesions improved the predictive accuracy 
of the nomogram predicting HGPCa. We found that removal 
of TRUS findings resulted in a small decrease in the AUC for 
predicting any cancer, but a larger decrease when predicting 
HGPCa (0.004 ver. 0.025). Further study is required to under-
stand the apparent link between the presence of hypoechoic 
lesions and HGPCa.
 We found that percent free PSA, which is accepted as a 
standard adjunct PSA test, had minimal predictive value in 
our study [4]. This finding is consistent with previous study 
showing that percent free PSA did not have better specificity 
than total PSA in Korean men aged <65 years with a palpa-
bly benign prostate gland and a PSA level of 4.0–10.0 ng/mL 
[11]. We found that age was the strongest factor in predicting 
both any cancer and HGPCa. The incremental drop in AUC 
when age was removed from the model was 0.077 for any 
cancer and 0.067 for HGPCa. Interestingly, these findings are 
similar to those of a study examining subjects with normal 
PSA levels (<4.0 ng/mL) [19]. In that study, age was a more 
powerful predictor than percent free PSA in the subset of men 
with healthy serum PSA levels, which differs from the find-
ings in men with increased PSA (>4 ng/mL). In addition, the 
detection rate of PCa observed in our study (20.6%) is similar 
to that reported in men with a healthy PSA level (24.3%), and 
is much lower than that observed in men with elevated PSA 
(44.6%) [19]. It is not clear why the present findings are simi-
lar to those in Western men with normal PSA levels. Further 
prospective comparative studies on the detection rate and 
detailed clinico-pathologic characteristics of detected PCa be-
tween Korean men with intermediate PSA ranges and West-
ern populations with normal PSA levels are needed.
 The present findings indicate that TRUS-derived informa-
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tion should be incorporated into nomograms predicting 
HGPCa in men with a PSA range of 4.0–9.9 ng/mL. Some cli-
nicians are reluctant to perform TRUS in men with increased 
PSA levels as they feel it is an invasive procedure. However, 
considering that curative therapy results in significantly im-
proved life expectancy even in older men with moderately 
or poorly differentiated localized PCa, physicians should be 
assessing the advantages and disadvantages of TRUS in men 
with intermediate PSA levels to assess the individualized risk 
for HGPCa [22].
 Previous study showed that extended biopsy-based nomo-
grams have greater accuracy than 6 –10 core biopsy-based no-
mograms in predicting PCa [23]. However, we did not include 
the method of prostate biopsy into our nomogram because a 
previous study showed that biopsy cores made no difference 
in the detection rate of PCa in Korean men with PSA levels of 
4.0–9.9 ng/mL [24]. 
 A limitation of the present study was that model valida-
tion was internal. Ideally, the predictive accuracy of a model 
should be tested using an external cohort. Therefore, greater 
understanding of the power of the present nomogram using 
TRUS-derived information awaits external validation in an-
other cohort.
 In conclusion, we developed a new nomogram using 
TRUS-derived information for predicting any cancer and HG-
PCa on initial biopsy in men with PSA levels 4.0–9.9 ng/mL. 
The nomogram using TRUS information had a high predictive 
accuracy for HGPCa. Our results indicate that TRUS-derived 
information should be included in predictive nomograms for 
HGPCa which most physicians are desirable to detect on ini-
tial biopsy.
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